Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions

P. Langevitz, D. Buskila, P. Lee, M. B. Urowitz

Research output: Contribution to journalArticlepeer-review

Abstract

Prostaglandin E1 (PGE1) is a potent vasodilator and inhibitor of platelet aggregation. We administered 20 PGE1 infusions to 12 patients with severe Raynaud's phenomenon, associated with refractory ischemic skin ulcers. There was symptomatic improvement following 17 of the 20 infusions, while 35 of the 65 ischemic ulcers healed between 2-6 weeks following treatment. The benficial effects persisted for between 1-18 months. While the treatment was well-tolerated in most patients, the procedure is not without risks. On the basis of this retrospective study, a trial of PGE1 infusion is recommended in the treatment of patients with ischemic skin ulcers, which have been refractory to other treatment modalities.

Original languageEnglish
Pages (from-to)1433-1435
Number of pages3
JournalJournal of Rheumatology
Volume16
Issue number11
StatePublished - 1989
Externally publishedYes

Keywords

  • Ischemic skin ulcers
  • Prostaglandin E
  • Raynaud's phenomenon
  • Scleroderma (systemic sclerosis)

Fingerprint

Dive into the research topics of 'Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions'. Together they form a unique fingerprint.

Cite this